Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50
Several vaccines have been approved for Covid-19 and effectiveness data could guide public health decisions on vaccine usage. Here, the authors compare effectiveness of BNT162b2 and ChAdOx1 vaccines in people over 50 in the UK and find that BNT162b2 confers lower risk of infection and hospitalizatio...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-03-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-022-29159-x |
| _version_ | 1818353628443836416 |
|---|---|
| author | Junqing Xie Shuo Feng Xintong Li Ester Gea-Mallorquí Albert Prats-Uribe Dani Prieto-Alhambra |
| author_facet | Junqing Xie Shuo Feng Xintong Li Ester Gea-Mallorquí Albert Prats-Uribe Dani Prieto-Alhambra |
| author_sort | Junqing Xie |
| collection | DOAJ |
| description | Several vaccines have been approved for Covid-19 and effectiveness data could guide public health decisions on vaccine usage. Here, the authors compare effectiveness of BNT162b2 and ChAdOx1 vaccines in people over 50 in the UK and find that BNT162b2 confers lower risk of infection and hospitalization. |
| first_indexed | 2024-12-13T19:12:33Z |
| format | Article |
| id | doaj.art-6853b812a22047b78ecb446cc8f8630f |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-12-13T19:12:33Z |
| publishDate | 2022-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-6853b812a22047b78ecb446cc8f8630f2022-12-21T23:34:22ZengNature PortfolioNature Communications2041-17232022-03-011311810.1038/s41467-022-29159-xComparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50Junqing Xie0Shuo Feng1Xintong Li2Ester Gea-Mallorquí3Albert Prats-Uribe4Dani Prieto-Alhambra5Centre for Statistics in Medicine, NDORMS, University of OxfordOxford Vaccine Group, Department of Paediatrics, University of OxfordCentre for Statistics in Medicine, NDORMS, University of OxfordNuffield Department of Clinical Medicine, University of OxfordCentre for Statistics in Medicine, NDORMS, University of OxfordCentre for Statistics in Medicine, NDORMS, University of OxfordSeveral vaccines have been approved for Covid-19 and effectiveness data could guide public health decisions on vaccine usage. Here, the authors compare effectiveness of BNT162b2 and ChAdOx1 vaccines in people over 50 in the UK and find that BNT162b2 confers lower risk of infection and hospitalization.https://doi.org/10.1038/s41467-022-29159-x |
| spellingShingle | Junqing Xie Shuo Feng Xintong Li Ester Gea-Mallorquí Albert Prats-Uribe Dani Prieto-Alhambra Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50 Nature Communications |
| title | Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50 |
| title_full | Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50 |
| title_fullStr | Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50 |
| title_full_unstemmed | Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50 |
| title_short | Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50 |
| title_sort | comparative effectiveness of the bnt162b2 and chadox1 vaccines against covid 19 in people over 50 |
| url | https://doi.org/10.1038/s41467-022-29159-x |
| work_keys_str_mv | AT junqingxie comparativeeffectivenessofthebnt162b2andchadox1vaccinesagainstcovid19inpeopleover50 AT shuofeng comparativeeffectivenessofthebnt162b2andchadox1vaccinesagainstcovid19inpeopleover50 AT xintongli comparativeeffectivenessofthebnt162b2andchadox1vaccinesagainstcovid19inpeopleover50 AT estergeamallorqui comparativeeffectivenessofthebnt162b2andchadox1vaccinesagainstcovid19inpeopleover50 AT albertpratsuribe comparativeeffectivenessofthebnt162b2andchadox1vaccinesagainstcovid19inpeopleover50 AT daniprietoalhambra comparativeeffectivenessofthebnt162b2andchadox1vaccinesagainstcovid19inpeopleover50 |